News

Press Release

Go to Topics

2021

Information about Litigation (Appeal) against Sysmex Corporation and its Subsidiary (PDF:135KB)
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2022 (PDF:441KB)
Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2021, and Revision of Full-Year Financial Forecasts (PDF:184KB)
Notice of Application for Selection of New Market Segment “Prime Market” on the Tokyo Stock Exchange (PDF:141KB)
Sysmex Launches Caresphere™ XQC, an External Quality Assessment App
- Enhancing the Reliability of Testing Results and Efficiency of Laboratory Operations with the Expansion of Caresphere - (PDF:165KB)
Sysmex Starts Implementing Job-Based HR Management System for All Employees (PDF:149KB)
Notice Concerning Absorption-Type Merger (Simplified/Short-Form Merger) of Wholly Owned Subsidiary (PDF:234KB)
Approval of "Genetic Diagnosis and Counseling for Inherited Retinal Dystrophy" Using Gene Panel Testing System for Advanced Medical Care B (PDF:202KB)
Information about Judgment of the Litigation against Sysmex Corporation and its Subsidiary (PDF:132KB)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2022
Sysmex Forms Strategic Alliance with QIAGEN for Providing Global Cancer Companion Diagnostics that Uses Ultra-sensitive Liquid Biopsy NGS Technology (PDF:205KB)
Our Views and Policy regarding Investment Unit Reduction (PDF:94KB)
Sysmex Obtains IVDR Certification for LYNOAMP™ CK19 E, a Gene Amplification Detection Reagent
- Prompt response to legislative changes in the European region that demand greater product safety - (PDF:184KB)
Th2 Chemokine TARC Kit "HISCL™ TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation risk (PDF:210KB)
SARS-CoV-2 antibody status in patients with cancer during the COVID-19 pandemic in Japan (PDF:205KB)
Sysmex Relocates its PCR Testing Laboratory to its Research and Development Center for Expanded Functions (PDF:154KB)
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2021
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2021 (PDF:174KB)
Announcement of Executive Change (PDF:176KB)
Sysmex Announces New Group Mid-Term Management Plan
- Harnessing Groupwide Capabilities and Promoting Corporate Reforms with a View to Sustainable Growth - (PDF:210KB)
Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance
- Commencing development of novel AI-based cell analyzers and testing techniques - (PDF:255KB)
Sysmex Obtains Manufacturing and Marketing Approval for Novel Coronavirus Detection Reagent (RT-PCR Method)
- Building a Self-Sufficient Production System in Japan for a Stable Supply of PCR Testing Kits - (PDF:169KB)
Sysmex Continues to Evolve Its Hematology Product Portfolio
- Flagship Model XR-Series and Compact 3-part WBC Differential Model XQ-Series to Be Rolled Out Sequentially - (PDF:209KB)
Announcement of Organizational and Personnel Changes (PDF:385KB)
Sysmex Presents Academic Report on Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021) - (PDF:118KB)
Sysmex Obtains Manufacturing and Marketing Approval for an Influenza A/B Virus Antigen Detection Test Kit
Influenza can be simultaneously measured in a short period of time in the same the novel coronavirus (SARS-CoV-2) antigen sample using the HISCL™-5000/HISCL-800 Automated Immunoassay Systems - h (PDF:170KB)
Sysmex Receives Approval for a Partial Change to the OncoGuide™ NCC Oncopanel System for Use in Cancer Genome Profiling
- Detection of 10 New Gene Mutations Including MSH6 and PMS2, NTRK3 Gene Fusion and Microsatellite Instability - (PDF:238KB)
Insurance Coverage Received for HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in SARS-CoV-2-Positive Patients (PDF:192KB)
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2021 (PDF:452KB)
Sysmex and Siemens Healthineers Extend Long-standing Global Alliance in Hemostasis Testing (PDF:148KB)
Sysmex Establishes New Subsidiary in Portugal
- Increasing Portuguese Market Presence by Enhancing Sales and After-Sales Support Networks - (PDF:163KB)
Sysmex and Yamato Logistics to Commence GDP-Compliant Transport of Reagents for Gene Testing at the Ultralow Temperature Range of Minus 70 Degrees Celsius or Below
- Also Commencing Experiments for Ultralow Temperature Transport Without Using Dry Ice - (PDF:251KB)
Sysmex Selected as One of the Global 100's Most Sustainable Companies in the World for the Fourth Time (PDF:173KB)
Sysmex and Roche Renew Agreement for Global Alliance
- Transforming a long-standing alliance into one for the next generation - (PDF:145KB)